Project Grant HT94252410424
Award Date
6/1/24
Completion Date
5/31/27
Dollars Obligated
$654K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Boston, MA 02114, USA
Similar Awards
The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), was awarded a $577,094 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to conduct research aimed at "Redirecting Viral Immunity to Eradicate Low Tumor Mutation Burden Lung Cancers." The award period runs from Aug 31, 2023 to Aug 29, 2025. As a leading academic medical center and research institution, MGH utilizes its...
This federal Project Grant award from the Defense Health Agency, under the Military Medical Research and Development (CFDA 12.420) program, provides $1,270,020.00 to support the development of personalized cancer vaccines targeting tumor heterogeneity and reprogramming the cold tumor micro-environment in kidney cancer. The award was granted to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), a renowned nonprofit academic medical center, to conduct this...
The Department of the Army Medical Command awarded a $1,498,368 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), with a performance period from August 1, 2024 to July 31, 2027. The grant will fund research to elucidate the molecular mechanisms of tumor-immune dynamics and evolution in response to radiation, in order to optimize treatment of high- and very...
The Defense Health Agency awarded a $1,621,712 Project Grant to The General Hospital Corporation's Research Management Division, operating as Massachusetts General Hospital (MGH), for the "THERAPEUTIC TARGETING OF CHEMORESISTANT RHABDOMYOSARCOMA" project. This award is funded through the Military Medical Research and Development program (CFDA 12.420), which supports a range of biomedical research initiatives to improve health outcomes for military service members, veterans, and the...
The U.S. Department of the Army Medical Command awarded a $992,302 Project Grant (CFDA 12.420 - Military Medical Research and Development) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to conduct research on "Targeting MHCII Ubiquitination to Induce Immune Regulation in Vascularized Composite Tissue Transplantation." The three-year project, beginning on September 15, 2025 and ending on September 14, 2028, aims to explore innovative...
The Defense Health Agency awarded Massachusetts General Hospital a $582,732 project grant under the Military Medical Research and Development program to conduct research titled "Metabolic Targets to Overcome Chemoradiation Resistance in Genotype-Defined Non-Small Cell Lung Carcinoma." The CFDA number for the program is 12.420. Through this award spanning July 1, 2023 to June 30, 2025, MGH will investigate medical solutions for lung cancer treatment in military service members and the...
The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), has been awarded a $1,000,236.00 Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420). The grant, effective April 1, 2024 through March 31, 2028, will fund research to "UNLOCK THE CTDNA MUTATIONAL PATTERNS FOR EARLY CANCER DETECTION AND NONINVASIVE BIOMARKERS." As a leading academic medical center and research...
The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), received a $1,865,846 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) on July 1, 2024. The funding will support the project "TARGETING NEUROIMMUNE AND EPITHELIAL SIGNALING FOR ECZEMA TREATMENT" through June 30, 2028. MGH, a leading academic medical center and research institution, will conduct biomedical research,...
This Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420) provides $730,033 to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), for research to develop therapies targeting AMH signaling within the ovarian cancer tumor microenvironment. The award has a performance period from April 15, 2024 to April 14, 2027. As part of its extensive biomedical research portfolio,...
The U.S. Department of Defense's Military Medical Research and Development program (CFDA 12.420) awarded a $2,328,936 Project Grant to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), for a 3-year research project titled "Elucidating Tumor Intrinsic and Extrinsic Drivers of Mucosal Melanoma". The grant, awarded on Sep 30, 2023, will fund MGH's biomedical research efforts to study the genetic and epigenetic landscape of mucosal melanoma,...